Pharmaceuticals
Evidence: Strong (FDA-approved)
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native GLP-1, modified with amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, extending half-life to approximately 7 days. Centrally, it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, reducing hunger and increasing satiety. Peripherally, it slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta-cells, and reduces glucagon secretion, providing comprehensive metabolic regulation.
Standard: Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.
Loading: Research indicates gradual dose escalation over 16-20 weeks to minimize GI side effects: 0.25 mg x 4 weeks → 0.5 mg x 4 weeks → 1.0 mg x 4 weeks → 1.7 mg x 4 weeks → 2.4 mg weekly.
Maintenance: Research indicates the highest tolerated dose within the approved range (typically 1.0-2.4 mg weekly SC) for weight management. 0.5-1.0 mg weekly may suffice for metabolic optimization without maximal weight loss.
Administration: subcutaneousoral
Timing: SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.
Duration: Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).
Semaglutide has the strongest clinical evidence of any compound in this database for weight loss (15-17% body weight reduction in STEP trials, 20% cardiovascular risk reduction in SELECT trial). It is FDA-approved for both T2DM (Ozempic) and weight management (Wegovy). The weight regain problem upon discontinuation is significant — most clients will need long-term use. Lean mass preservation requires concurrent resistance training and adequate protein intake (1.2-1.6 g/kg/day). GI side effects are dose-limiting for many clients; slow titration is essential. For metabolic optimization without maximal weight loss, lower doses (0.5-1.0 mg) may provide metabolic benefits with fewer side effects. This is the most evidence-based metabolic intervention in the database.
Pharmaceutical-grade only (Wegovy for weight, Ozempic for T2DM, Rybelsus for oral). Compounded semaglutide is widely available but quality varies significantly — verify through reputable 503B pharmacy.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →